KORU Medical (KRMD) Q4 2025 earnings review
Growth Accelerates as KORU Turns Cash Flow Positive
KORU Medical delivered a milestone quarter, achieving 23% revenue growth to $10.9M and generating positive cash flow. The company has officially pivoted from a cash-burning growth story to a sustainable, self-funding operation, reporting $0.5M in Adjusted EBITDA for Q4. International expansion was the primary growth engine, surging 71% YoY. However, top-line success masked underlying margin pressures, as gross margins compressed due to tariffs and unfavorable geographic mix. Looking ahead, management expects continued momentum, initiating 2026 guidance of 15-22% revenue growth and full-year positive cash flow.
🐂 Bull Case
The company has achieved positive Adjusted EBITDA for three consecutive quarters and generated $0.4M in cash during Q4. The burn rate has been largely eliminated.
International Core revenue growth accelerated to 71% in Q4, driven by the structural shift from vials to prefilled syringes in Europe. The newly announced Freedom60 EU MDR certification will likely sustain this momentum.
🐻 Bear Case
Despite a 23% surge in total revenue, gross margin compressed 30 basis points to 62.6%. Tariffs, material costs, and a growing mix of lower-ASP international sales are capping profitability gains.
The Pharma Services and Clinical Trials (PST) segment unexpectedly contracted 30% YoY in Q4, highlighting the lumpy, unpredictable nature of this revenue stream.
⚖️ Verdict: 🟢
Bullish. The 23% top-line growth combined with the inflection to positive cash flow validates management's strategy. While gross margins face structural headwinds, operating leverage is successfully driving the company into sustainable profitability.
Key Themes
International Core Expansion
International revenue is accelerating rapidly, growing 71.3% YoY in Q4 to $2.58M and 80.0% for the full year. This is being driven by the ongoing conversion of European markets from vials to prefilled syringes (PFS). With KORU's system being uniquely positioned for PFS compatibility compared to legacy electronic pumps, this segment is transitioning from an emerging opportunity into the primary growth engine.
Therapeutic and Regulatory Platform Expansion
KORU is successfully executing its strategy to move beyond its core Immunoglobulin (Ig) market. The company recently received 510(k) clearance for UCB RYSTIGGO, broadening its therapeutic applications. Furthermore, the newly announced Freedom60 EU MDR certification with prefilled syringe compatibility de-risks the European regulatory pathway and secures future commercialization.
Domestic Core Resilience
Following a Q3 dip caused by a specific distributor inventory reduction, the Domestic Core rebounded strongly, posting 17.8% growth to $7.8M in Q4. This segment remains the bedrock of the company, with growth driven by underlying subcutaneous immunoglobulin (SCIg) market expansion and sustained market share gains.
Pharma Services (PST) Contraction
A clear negative divergence emerged in the PST segment, which fell 30.1% YoY to $0.47M in Q4. Management attributed this to lower NRE collaboration revenue tied to milestone timing. While a smaller part of the overall business (4.3% of Q4 sales), this contraction contradicts the broader growth narrative and highlights the lumpiness of collaboration revenues.
Macro Headwinds Squeezing Gross Margins
Gross margins remain stuck below historical levels, coming in at 62.6% for Q4 (down from 62.9% a year ago) and 62.3% for the full year. Management explicitly called out higher material costs and tariff-related charges as primary drivers of this compression, which were only partially offset by higher average selling prices in the US.
Geographic Mix Pressuring Profitability
Because the rapidly growing International segment carries lower Average Selling Prices (ASPs) than the Domestic segment, KORU's overall gross margin faces structural pressure as international sales make up a larger percentage of total revenue (rising from 18% to 26.5% of FY sales). Cost optimization will be required to prevent this mix shift from eroding long-term bottom-line potential.
Other KPIs
Reversing trajectory. Adjusted EBITDA swung from a loss of $0.7M in Q4 2024 to a profit of $0.5M in Q4 2025. For the full year, Adjusted EBITDA hit $0.6M, a massive $3.1M turnaround from 2024. This validates that top-line growth is finally flowing through to the bottom line.
Stable. Total operating expenses grew a mere 3.0% YoY in Q4, dramatically lagging the 23.3% revenue growth. This demonstrates excellent operating leverage, as management contained costs while scaling production, though the slight OpEx increase was driven by 2024 performance-based compensation.
The company generated $0.4M in cash during Q4, reducing full-year cash usage to just $0.7M (a 63% YoY improvement). The $8.9M ending cash balance is more than sufficient to fund operations given the recent pivot to positive cash generation.
Guidance
Stable to slightly decelerating. The midpoint ($48.75M) implies an 18.5% YoY growth rate. While this is slightly lower than the 22.2% growth achieved in 2025, it represents sustained, robust double-digit expansion, likely anchored by international PFS conversions.
Stable. This range surrounds the 62.3% achieved in FY25. The flat margin guidance indicates that management expects ongoing headwinds from tariffs, material costs, and an unfavorable geographic mix (due to high international growth) to persist through 2026.
Accelerating. Guiding for positive results on a full-year basis solidifies the operational turnaround seen in the second half of 2025, removing near-term equity dilution risks.
Key Questions
PST Segment Volatility
Pharma Services revenue declined 30% in Q4 due to milestone timing. Given your new collaborations, what is the expected revenue cadence for PST in 2026, and how much visibility do you currently have into milestone achievements?
Gross Margin Pathway
Your 2026 gross margin guidance implies a ceiling of 63%, hampered by tariffs and geographic mix. What specific cost-down or supply chain initiatives are in place to eventually drive margins back toward the historical 65%+ level?
EU MDR Certification Impact
With the newly announced Freedom60 EU MDR certification, do you expect this to accelerate the timeline for pharmaceutical partners transitioning from vials to prefilled syringes in European markets?